Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Relapsed/Refractory Follicular Lymphoma With EZH2

Interventions

DRUG

Tazemetostat

All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle

Trial Locations (1)

Shanghai Cancer Center, Shanghai